These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35116612)

  • 1. Vasculogenic mimicry in head and neck tumors: a narrative review.
    Yue Y; Lou Y; Liu X; Peng X
    Transl Cancer Res; 2021 Jun; 10(6):3044-3052. PubMed ID: 35116612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasculogenic mimicry in carcinogenesis and clinical applications.
    Luo Q; Wang J; Zhao W; Peng Z; Liu X; Li B; Zhang H; Shan B; Zhang C; Duan C
    J Hematol Oncol; 2020 Mar; 13(1):19. PubMed ID: 32169087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.
    Martini C; DeNichilo M; King DP; Cockshell MP; Ebert B; Dale B; Ebert LM; Woods A; Bonder CS
    BMC Cancer; 2021 Jul; 21(1):765. PubMed ID: 34215227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasculogenic Mimicry in Head and Neck Squamous Cell Carcinoma-Time to Take Notice.
    Salem A; Salo T
    Front Oral Health; 2021; 2():666895. PubMed ID: 35048009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP-2 expression.
    Wang Z; You D; Lu M; He Y; Yan S
    Oncol Lett; 2017 Mar; 13(3):1660-1664. PubMed ID: 28454306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Vasculogenic Mimicry in Breast Cancer.
    Andonegui-Elguera MA; Alfaro-Mora Y; Cáceres-Gutiérrez R; Caro-Sánchez CHS; Herrera LA; Díaz-Chávez J
    Front Oncol; 2020; 10():220. PubMed ID: 32175277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.
    Wei X; Chen Y; Jiang X; Peng M; Liu Y; Mo Y; Ren D; Hua Y; Yu B; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Xiong W; Zeng Z
    Mol Cancer; 2021 Jan; 20(1):7. PubMed ID: 33397409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research progress in vasculogenic mimicry in 
multiple tumors].
    Bai J; Xu Z; Liao C; Yang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 42(3):357-364. PubMed ID: 28364113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231.
    Xu MR; Wei PF; Suo MZ; Hu Y; Ding W; Su L; Zhu YD; Song WJ; Tang GH; Zhang M; Li P
    Biomed Res Int; 2019; 2019():6543230. PubMed ID: 30723742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasculogenic Mimicry: A Promising Prognosticator in Head and Neck Squamous Cell Carcinoma and Esophageal Cancer? A Systematic Review and Meta-Analysis.
    Hujanen R; Almahmoudi R; Karinen S; Nwaru BI; Salo T; Salem A
    Cells; 2020 Feb; 9(2):. PubMed ID: 32102317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer dissection of vasculogenic mimicry characteristic to provide potential therapeutic targets.
    Tang H; Chen L; Liu X; Zeng S; Tan H; Chen G
    Front Pharmacol; 2024; 15():1346719. PubMed ID: 38694917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer.
    Li S; Zhang Q; Zhou L; Guan Y; Chen S; Zhang Y; Han X
    Biomed Pharmacother; 2017 Dec; 96():982-992. PubMed ID: 29208325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs.
    Hu H; Ma T; Liu N; Hong H; Yu L; Lyu D; Meng X; Wang B; Jiang X
    Int Immunopharmacol; 2022 Oct; 111():109116. PubMed ID: 35969899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasculogenic mimicry.
    Pandiar D; Smitha T; Krishnan RP
    J Oral Maxillofac Pathol; 2023; 27(1):228-229. PubMed ID: 37234296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas.
    Sun B; Zhang S; Zhao X; Zhang W; Hao X
    Int J Oncol; 2004 Dec; 25(6):1609-14. PubMed ID: 15547697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of vasculogenic mimicry in urological tumors.
    Lin X; Long S; Yan C; Zou X; Zhang G; Zou J; Wu G
    Front Oncol; 2023; 13():1202656. PubMed ID: 37810976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma.
    Liu WB; Xu GL; Jia WD; Li JS; Ma JL; Chen K; Wang ZH; Ge YS; Ren WH; Yu JH; Wang W; Wang XJ
    Med Oncol; 2011 Dec; 28 Suppl 1():S228-38. PubMed ID: 20957524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma.
    Sun B; Zhang S; Zhang D; Du J; Guo H; Zhao X; Zhang W; Hao X
    Oncol Rep; 2006 Oct; 16(4):693-8. PubMed ID: 16969481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered in vivo and in vitro tumor model recapitulates vasculogenic mimicry signatures in melanoma.
    Shuai Q; Xu X; Liang Y; Halbiyat Z; Lu X; Hu Z; Peng Z; An J; Feng Z; Huang T; Zhao H; Liu Z; Xu J; Xie J
    Bioeng Transl Med; 2024 Jul; 9(4):e10648. PubMed ID: 39036079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.